[March 22, 2013]

Research and Markets: Norvir (HIV) - Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/5bf4z9/norvir_hiv) has announced the addition of the "Norvir (HIV) - Forecast and Market Analysis to 2022" report to their offering.

Norvir (ritonavir) is a PI indicated in combination with other antiretroviral agents for the treatment of HIV infection. Unlike most PIs, which are prescribed due to their activity against the HIV protease, Norvir is commonly prescribed in combined with other protease inhibitors as a pharmacokinetic enhancer. Norvir increases the plasma levels of other PIs by inhibiting the cytochrome P450 enzyme CYP3A, which would otherwise decrease bioavailability and half-life of the PIs via metabolism (Norvir prescribing information, 2012). Therefore, while Novir can be administered as an antiretroviral agent, the drug will be considered as a pharmacokinetic enhancer for the purposes of this report since the drug is predominately prescribed for that purpose.

Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

Scope

- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Norvir including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Norvir for the top nine countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China

For more information visit http://www.researchandmarkets.com/research/5bf4z9/norvir_hiv

[ InfoTech Spotlight's Homepage ]